BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: May 5, 2025 · CIK: 882796
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K on 5/5/25, check financials.
AI Summary
On May 5, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, but does not specify any new material events or transactions.
Why It Matters
This 8-K filing provides an update on BioCryst Pharmaceuticals' financial status and operational results, which is important for investors to assess the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not indicate any unusual or negative developments.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- May 5, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on BioCryst Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, as well as to provide Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 5, 2025.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
BioCryst Pharmaceuticals, Inc.'s principal executive office is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is BioCryst Pharmaceuticals, Inc.'s telephone number?
BioCryst Pharmaceuticals, Inc.'s telephone number is (919) 859-1302.
What is the Standard Industrial Classification for BioCryst Pharmaceuticals, Inc.?
The Standard Industrial Classification for BioCryst Pharmaceuticals, Inc. is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 5, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).